[HTML][HTML] An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz, B Klimovich… - Molecular Therapy, 2023 - cell.com
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
[HTML][HTML] An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz, B Klimovich… - Molecular Therapy, 2023 - Elsevier
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
[HTML][HTML] An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz, B Klimovich… - Molecular …, 2023 - ncbi.nlm.nih.gov
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
L Zekri, M Lutz, N Prakash, T Manz… - … Therapy: the Journal …, 2023 - europepmc.org
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
[引用][C] An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz… - Molecular …, 2023 - tobias-lib.ub.uni-tuebingen.de
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal
cancers An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of …
cancers An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of …
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz… - … therapy: the journal …, 2023 - pubmed.ncbi.nlm.nih.gov
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
[引用][C] An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers
L Zekri, M Lutz, N Prakash, T Manz… - Molecular …, 2023 - ub01.uni-tuebingen.de
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal
cancers An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of …
cancers An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of …
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
L Zekri, M Lutz, N Prakash, T Manz… - … Therapy: the Journal …, 2023 - europepmc.org
T cell-based immunotherapy has revolutionized oncological treatment. However, many
patients do not respond to treatment, and long-term remissions remain rare, particularly in …
patients do not respond to treatment, and long-term remissions remain rare, particularly in …